

BIOLIDICS LIMITED
(Company Registration No.: 200913076M)
(Incorporated in the Republic of Singapore)

**PROPOSED ACQUISITION OF THE ENTIRE ISSUED AND PAID-UP ORDINARY SHARES IN THE
CAPITAL OF BIOMEDICS LABORATORY PTE. LTD. – COMPLETION**

1. INTRODUCTION

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**") refers to the Company's announcement on 27 March 2020 and the circular to shareholders dated 8 April 2020 (the "**Circular**") in relation to the Proposed Acquisition.

All capitalised terms used in this announcement which are not defined shall have the same meaning ascribed to them in the Circular.

2. COMPLETION OF THE PROPOSED ACQUISITION

The Board is pleased to announce that the Proposed Acquisition has been completed today in accordance with the terms and conditions of the SPA. Accordingly, Biomedics Laboratory Pte. Ltd. is now a wholly-owned subsidiary of the Company.

3. FURTHER ANNOUNCEMENTS

The Company will make further announcements to keep shareholders informed on the payment of the Deferred Consideration.

BY ORDER OF THE BOARD

Leong Yow Seng
Lead Independent Director
26 May 2020

*This announcement has been prepared by Biolidics Limited (the "**Company**") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.